MedTrace Logo

Platelet Inhibition in Patients With Systolic Heart Failure

NCT01765400 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-10-10

Study results available
· View outcomes & findings →

Summary

The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.

Conditions

  • Systolic Heart Failure

Interventions

DRUG

Prasugrel 10 mg daily x 2 weeks

DRUG

Clopidogrel 75 mg daily x 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Paul P Dobesh, PharmD · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-15
Primary Completion
2015-12-01
Completion
2015-12-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01765400 on ClinicalTrials.gov